Hematology Am Soc Hematol Educ Program , 2019 (1), 315322
IGF-1 is crucial for growth through adolescence, and for cell health and survival throughout life

Your GP can: Assess your current weight, BMI, and metabolic health to determine clinical need Review existing treatment options that are currently licensed and available in the UK, which may include orlistat, naltrexone/bupropion (Mysimba), semaglutide 2.4 mg (Wegovy approved by the MHRA for weight management and subject to NICE guidance on eligibility, service setting, and treatment duration), and tirzepatide (Mounjaro check current MHRA and NICE status at the time of reading, as licensing and commissioning arrangements may have been updated) Discuss eligibility for NHS Tier 3 or Tier 4 specialist weight management services , in line with NICE guidance on obesity management, where pharmacotherapy is used as an adjunct to structured lifestyle intervention Signpost you to relevant clinical trials via the Be Part of Research portal or ClinicalTrials.gov if you wish to explore participation in retatrutide research It is important to approach information about investigational medicines with appropriate caution

[14] Ilic D, Forbes KM, Hassed C
Standard Clinical Criteria for Prescription: A BMI of 30 or higher: This is classified as obesity and is the primary threshold for most weight-loss-specific GLP-1 medications